CELLCEUTIX, Inc. (NASDAQOTH:CTIX)

CAPS Rating: 1 out of 5

Results 1 - 4 of 4

Recs

0
Member Avatar eyezie1 (29.68) Submitted: 4/9/2014 2:47:04 AM : Outperform Start Price: $1.57 CTIX Score: +19.57

Brilacidin is a competitor of Cubist and Durata for use in gram positive infections. FDA is fast tracking antibiotics.

Recs

0
Member Avatar adi101 (87.62) Submitted: 3/2/2014 7:45:11 AM : Outperform Start Price: $1.95 CTIX Score: -5.65

clinical stage, 3 drugs in development: new antibiotic, anti psoriasis, cancer drug.

Recs

0
Member Avatar kmac28 (< 20) Submitted: 12/9/2013 6:49:02 AM : Outperform Start Price: $1.62 CTIX Score: +13.22

Fully dependent on current FDA trials at Dana Farber Cancer institute in MA.

Recs

0
Member Avatar jed71 (31.29) Submitted: 9/12/2013 11:38:55 AM : Underperform Start Price: $1.97 CTIX Score: +16.61

Pump N Dump scam.

Results 1 - 4 of 4

Featured Broker Partners


Advertisement